Siddharth Padia, MD, discusses the utility of TheraSphere™ Yttrium-90 Glass Microspheres in patients with hepatocellular carcinoma.
Siddharth Padia, MD
Advertisement
Articles by Siddharth Padia, MD
Siddharth Padia, MD, discusses the data that led to the March 2021 FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres for use in patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
2
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
3
Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera
4
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
5